Lexicon Pharmaceuticals (LXRX) FCF Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly FCF Margin of 69.8% for Q1 2026, up 339913.0% year-over-year from N/an in Q1 2025, and up 77.75% quarter-over-quarter from 313.73% in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) FCF Margin (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported FCF Margin for 16 consecutive years, with 69.8% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 339913.0% year-over-year to 69.8%; the TTM figure through Mar 2026 stood at 55.72% (up 48399.0% YoY), while the FY2025 annual figure was 136.24%, up 44229.0% from the prior year.
- FCF Margin advanced to 69.8% in Q1 2026 per LXRX's latest filing, from 313.73% in the prior quarter.
- Across five years, FCF Margin topped out at 58.87% in Q2 2025 and bottomed at 69777.14% in Q2 2022.
- Historically, FCF Margin has averaged 10030.51% across 5 years, with a median of 3081.49% in 2024.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 5663075 bps — and 2025, when it slumped 23101 bps.
- Lexicon Pharmaceuticals' FCF Margin stood at 69777.14% in 2022, then jumped by 91 bps to 6598.96% in 2023, then jumped by 99 bps to 82.72% in 2024, then sank by 279 bps to 313.73% in 2025, then jumped by 78 bps to 69.8% in 2026.
- Business Quant data shows LXRX's FCF Margin at 69.8% in Q1 2026, 313.73% in Q4 2025, and 168.05% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -1,328.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,328.32% |
| Mar 31, 2026 | -69.80% |
| Dec 31, 2025 | -313.73% |
| Sep 30, 2025 | -168.05% |
| Jun 30, 2025 | 58.87% |
| Mar 31, 2025 | -3,468.94% |
| Dec 31, 2024 | -82.72% |
| Sep 30, 2024 | -3,081.49% |
| Jun 30, 2024 | -2,962.36% |
| Mar 31, 2024 | -4,878.76% |
| Dec 31, 2023 | -7,200.57% |
| Sep 30, 2023 | -25,741.98% |
| Jun 30, 2023 | -12,068.14% |
| Mar 31, 2023 | -132,754.17% |
| Dec 31, 2022 | -81,482.14% |
| Sep 30, 2022 | -49,853.85% |
| Jun 30, 2022 | -69,777.14% |
| Dec 31, 2021 | -163,221.43% |
| Sep 30, 2021 | -75,491.30% |
| Jun 30, 2021 | -9,755.13% |